BIOTECH BY THE LAKE 2020
INVESTOR SUMMIT

Thursday, May 28, 2020
9:00 – 11:45 a.m. Central Standard Time

WELCOME
9:00 a.m. Thomas V. O’Halloran, PhD, Founding Director, Chemistry of Life Processes Institute at Northwestern University

NORTHWESTERN FACULTY PRESENTATIONS
9:05 a.m. Nathan Gianneschi, PhD, Jacob and Rosaline Cohn Professor of Chemistry, Departments of Chemistry, Materials Science & Engineering, Biomedical Engineering and Pharmacology: “Protein-Like Polymers: A Peptide Therapeutic Delivery Platform Technology”

9:25 a.m. Daniela Elena Matei, MD, Diana, Princess of Wales Professor of Cancer Research Professor of Medicine (Hematology and Oncology) and Obstetrics and Gynecology: “Tissue Transglutaminase/Fibronectin Interaction, a Potential New Cancer Target”

9:45 a.m. Josh Leonard, PhD, Associate Professor of Chemical and Biological Engineering Charles Deering McCormick Professor of Teaching Excellence: “Design-driven engineering of programmable cell-based therapies through synthetic biology”
10:05 a.m.

**PANEL DISCUSSION | HOT TOPICS IN CANCER THERAPEUTICS AND TECHNOLOGIES**

*Simone Fishburn, PhD, VP and Editor in Chief, BioCentury Inc. (Moderator)*

*Andrew Chan, MD, PhD, Senior Vice President of Research Biology, Genentech*

*Elizabeth McNally, MD, PhD, Director, Center for Genetic Medicine; Elizabeth J. Ward Professor of Genetic Medicine; Professor of Medicine (Cardiology) and Biochemistry and Molecular Genetics, Northwestern Feinberg School of Medicine*

*Neil Kelleher, PhD, Walter and Mary E. Glass Professor of Molecular Biosciences; Professor of Chemistry; and Professor, Biochemistry and Molecular Genetics and Medicine, Faculty Director, Northwestern Proteomics, Northwestern University*

*Nick Saccomano, PhD, CSO-SVP, Pfizer Boulder Research and Development*

**CORPORATE PRESENTATIONS**

10:25 a.m.  *Barbara Klencke, MD, Chief Development Officer, Sierra Oncology (SRRA)*

10:45 a.m.  *Mani Mohindru, PhD, Chief Executive Officer, CereXis*

11:05 a.m.  *Jonathan Zalevsky, PhD, Chief Research and Development Officer, Nektar (NKTR)*

11:25 a.m.

**PANEL DISCUSSION: MIDWEST BIOTECH INVESTMENT OUTLOOK**

*Jay Olson, CFA, Research Analyst, Oppenheimer & Co. (Moderator)*

*Vanessa Bhark, Senior Associate, Frazier Healthcare Partners*

*Maha Katabi, PhD, CFA, General Partner, Sofinnova Investments*

*Michael Margolis, R Ph, Managing Director, Oppenheimer & Co.*

*Alex Munns, Assistant Portfolio Manager, Senior Analyst, Driehaus Capital*

11:45 p.m.  **CLOSING REMARKS**
Thomas O’Halloran, PhD
Founding Director, Chemistry of Life Processes Institute
Charles E. and Emma H. Morrison Professor of Chemistry and Professor of Molecular Biosciences, Weinberg College of Arts & Sciences; Northwestern University
Professor of Medicine, Division of Hematology and Oncology, Feinberg School of Medicine

Thomas V. O’Halloran, PhD, is a widely respected and internationally recognized expert in bioinorganic chemistry. His research focuses on understanding how receptors for metals such as copper, iron and zinc regulate cellular functions across organisms that span the tree of life. Using genetic, chemical, structural and mechanistic approaches, he and his collaborators have discovered new types of metal-binding proteins, defined their structures, functions and mechanisms and tied their function to a number of disease-related physiological processes. Among many other breakthroughs, Tom and collaborators discovered that zinc fluxes control fundamental developmental decisions in bacteria, diseases-causing parasites and fertilization of mammalian eggs. Over five hundred press pieces have been published about the zinc fluxes and sparks that accompany fertilization of mammalian eggs.

Tom is the Charles E. and Emma H. Morrison Professor in Chemistry and Professor of Molecular Biosciences in the Weinberg College of Arts & Sciences and Professor in the Department of Medicine, Division of Hematology and Oncology in the Feinberg School of Medicine at Northwestern University. He is the founding director of the Chemistry of Life Processes Institute (CLP) and director of the Institute’s Quantitative Bio-element Imaging Center and Center for Developmental Therapeutics. Tom is the principal investigator of the Chicago Region Physical Science-Oncology Center (CR-PSOC), a partnership between CLP and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Tom co-founded several successful biomedical startups including Tactic Pharma that led to the spin-out of Monopar Therapeutics, the largest first day increase for IPO since 2005. Among his many awards and honors, Tom gave the Annual Dewitt Stetten Jr. Lecture at NIH in September 2016 and is a Fellow of AAAS and the Royal Society of Chemistry.
NORTHWESTERN FACULTY PRESENTATIONS

9:05 a.m.
“Protein-Like Polymers: A Peptide Therapeutic Delivery Platform Technology”

Nathan Gianneschi, PhD
Jacob and Rosaline Cohn Professor of Chemistry, Departments of Chemistry, Materials Science & Engineering, Biomedical Engineering and Pharmacology, Northwestern University

Nathan C. Gianneschi, PhD, received his B.Sc (Hons) at the University of Adelaide, Australia in 1999. In 2005 he completed his PhD at Northwestern University. Following a Dow Chemical postdoctoral fellowship at The Scripps Research Institute in 2008, he began his independent career at the University of California, San Diego where, until June 2017, he was Teddy Traylor Scholar and Professor of Chemistry & Biochemistry, Nano Engineering and Materials Science & Engineering. In July of 2017, Nathan moved his research group to Northwestern University where he is currently Jacob & Rosaline Cohn Professor of Chemistry, Materials Science & Engineering, and Biomedical Engineering. The Gianneschi Group takes an interdisciplinary approach to nanomaterials research with a focus on multifunctional materials with interests that include biomedical applications, programmed interactions with biomolecules and cells, and basic research into nanoscale materials design, synthesis and characterization. For this work, he has been awarded the NIH Director's New Innovator Award, the NIH Director's Transformative Research Award and the White House's highest honor for young scientists and engineers with a Presidential Early Career Award for Scientists and Engineers. Nathan was awarded a Dreyfus Foundation Fellowship, is a Kavli Fellow of the National Academy of Sciences, a Fellow of the Royal Society of Chemistry, and is an Alfred P. Sloan Foundation Fellow.

Q&A

9:25 a.m.
“Tissue Transglutaminase/Fibronectin Interaction, a Potential New Cancer Target”

Daniela Elena Matei, MD
Diana, Princess of Wales Professor of Cancer Research Professor of Medicine (Hematology and Oncology) and Obstetrics and Gynecology
Feinberg School of Medicine
Northwestern University

Daniela Matei, MD, is a Professor in the Department of Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine and the co-Leader of the Translational Research is Solid Tumors Program in the Robert H. Lurie Comprehensive Cancer Center. She is a physician scientist well known in the field of ovarian cancer. Daniela earned her MD from the University of Medicine and Pharmacy “Carol Davila” in Bucharest, Romania and completed post-graduate training at SUNY at Stony Brook and at UCLA.

May 28, 2020
#biotechbythelake

Supported by:
BioCentury
Chemistry of Life Processes Institute
Oppenheimer
She was a Professor at Indiana University in the Division of Hematology Oncology and served as the Co-leader of the Experimental and Developmental Therapeutics Program of the Indiana University Simon Cancer Center since 2007. Daniela’s research has been continuously funded by the National Cancer Institute, the US Department of Veteran Affairs, the Department of Defense, the American Cancer Society, the V Foundation, and the Ovarian Cancer Research Fund.

Daniela’s laboratory studies mechanisms of ovarian cancer metastasis and novel therapeutics for ovarian cancer. The general theme is translation between bench and clinic; with laboratory research forming the foundation of clinical experiments. She is also engaged in clinical research and serves as the principal investigator and/or co-investigator on many clinical trials testing novel therapies for ovarian cancer, including several cooperative group and National Cancer Institute – sponsored trials for gynecologic cancer.

Q&A

9:45 a.m.
“Design-driven engineering of programmable cell-based therapies through synthetic biology”

Josh Leonard, PhD
Associate Professor of Chemical and Biological Engineering
Charles Deering McCormick Professor of Teaching Excellence
Northwestern University

Josh Leonard, PhD, is Associate Professor of Chemical and Biological Engineering Charles Deering McCormick Professor of Teaching Excellence at Northwestern University. His research group works at the interface of systems biology and synthetic biology in order to probe and program the function of complex, multicellular systems to develop transformative biotechnologies and enable a new paradigm of design-driven medicine.

Using the tools of synthetic biology, biomolecular engineering, computational systems biology, and gene therapy, Josh develops technologies including programmable cell-based “devices,” immune therapies for cancer and chronic disease, smart vaccines, biosensors for global health applications, and tools for advanced metabolic engineering. By bringing an engineering approach to the investigation, design, and construction of biological systems, the Leonard Group is advancing the frontiers of design-driven medicine to address unmet medical needs and create safe, effective, and long-lasting treatment options that improve both quantity and quality of life.

Q&A
10:05 a.m.
PANEL DISCUSSION: HOT TOPICS IN CANCER THERAPEUTICS AND TECHNOLOGIES

Simone Fishburn, PhD (Moderator)
VP & Editor in Chief
BioCentury Inc.

SimoneFishburn, PhD, serves as Vice President and Editor in Chief, bringing experience from both industry and academia in translational science, where she focused for over 15 years on the scientific, commercial and strategic considerations for advancing laboratory discoveries to products for patients.

Since joining BioCentury in 2013, Simone has written and edited on innovation from idea to patient, most recently serving as Executive Editor. Previously, she was a director of translational research at Nektar Therapeutics and a senior managing consultant at Exponent Inc., where she specialized in projects for the biopharma industry. Simone serves as an adviser on multiple university translational programs, including initiatives at the University of California and Stanford University. Simone is also active in programs to advance women's careers; she is a board member of Women In Bio and served as its President in 2013-14.

Simone is a Fulbright scholar and performed a post-doc at the University of California San Francisco. She holds a Ph.D. in Molecular Pharmacology from the Weizmann Institute of Science, and an M.A. and B.A. in Pharmacology from Cambridge University.

Panelists:

Andrew Chan, MD, PhD
Senior Vice President of Research Biology
Genentech (RHHBY)

Andrew C. Chan, MD, PhD, serves as Senior Vice President of Research Biology at Genentech, Inc. Previously, he served as Senior Vice President of Immunology at Genentech Inc. Andy was responsible for overseeing research programs focused on the role of the immune system in cancer and various immunological disorders. He served as Vice President, Research-Immunology of Genentech, Inc. since July 17, 2003. He continued to supervise Genentech's immunology research program for the treatment of immune-mediated and inflammatory disorders. Andy's laboratory is currently working on defining the role of B-cells in autoimmune disease and understanding the mechanisms of action of anti-CD20 and other B-cell modulatory therapies. Andy joined Genentech, Inc. in 2001 as senior Director of Immunology in the Research department.

Andy holds a Bachelor’s and Master’s degrees in chemistry from Northwestern University and a Medical Degree and Doctorate in cellular and developmental biology from the Washington University School of Medicine in St. Louis. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University School of Medicine before becoming a postdoctoral clinical and research fellow at the University of California, San Francisco.
joining Genentech, Andy was an associate professor in the Division of Rheumatology and the Departments of Medicine, Pathology and Immunology at Washington University School of Medicine in St. Louis, where he was also a Howard Hughes Medical Institute (HHMI) associate investigator. Andy is a frequent lecturer and has authored or co-authored more than 50 scientific articles.

Elizabeth McNally, MD, PhD
Director, Center for Genetic Medicine; Elizabeth J. Ward Professor of Genetic Medicine; Professor of Medicine (Cardiology) and Biochemistry and Molecular Genetics, Northwestern Feinberg School of Medicine

Elizabeth McNally, MD, PhD, is a professor in the Departments of Medicine and Biochemistry, Molecular Biology and Genetics at Northwestern University Feinberg School of Medicine, where she directs the Center for Genetic Medicine. Elizabeth is a cardiologist who specializes in caring for inherited forms of heart disease. Elizabeth research has been to identify genes and the mechanisms by which genetic defects lead to heart and muscle disease. A major focus in the laboratory is now to uncover genetic modifiers of single gene disorders.

Elizabeth received her undergraduate degree from Barnard College at Columbia University in New York majoring in Biology and Philosophy. She was awarded MD and PhD degrees from the Albert Einstein College of Medicine where she participated in the NIH-sponsored Medical Scientist Training Program. Elizabeth trained in Internal Medicine and Cardiovascular Medicine at the Brigham and Women’s Hospital and Harvard Medical School. Her postdoctoral fellowship was at Children’s Hospital in Boston in the Division of Genetics and the Howard Hughes Medical Institute. In addition to her research, Elizabeth is an active physician who established one of the very first Cardiovascular Genetics Clinics in the nation. This clinic, now at Northwestern, provides counseling and cardiovascular care for those with inherited cardiovascular disorders.

Elizabeth advocates for patients and medical research through her work with the Muscular Dystrophy Association and Parent Project Muscular Dystrophy Foundation, where she serves on advisory boards. She was president of the American Society for Clinical Investigation (2011-2012). Elizabeth has been recognized as an Established Investigator of the American Heart Association and as a Distinguished Clinical Scientist by the Doris Duke Charitable Foundation.

Neil Kelleher, PhD
Walter and Mary E. Glass Professor of Molecular Biosciences; Professor of Chemistry; and Professor, Biochemistry and Molecular Genetics and Medicine, Faculty Director, Northwestern Proteomics Northwestern University

After finishing his joint graduate work with Tadhg Begley and Fred McLafferty at Cornell University in 1997, Neil Kelleher, PhD, moved to the laboratory of Christopher Walsh at Harvard Medical School. This training in high performance mass spectrometry and enzymology explains much of the research performed by his independent laboratory over the last decade at the University of Illinois in Urbana-Champaign.

In 2010, the Kelleher Group relocated to Northwestern University where the three main sub-groups continue working in the areas of Top Down Proteomics, Natural Products Biosynthesis/Discovery,
and Chromatin Biology. Neil has been successful in driving both technology development and applications of very high performance mass spectrometry in both chemistry and biology. He has over 350 publications, an H-factor of 70, and provides ProSight software via the web to over 500 labs around the world.

The core of the Kelleher Team is built around expertise in technology development for complex mixture analysis using Fourier-Transform Mass Spectrometry for targeted applications in proteomics and metabolomics. Neil harbors specific interests in the biosynthesis and discovery of polyketides and non-ribosomally produced peptides. Further themes of the Kelleher laboratory include using intact proteins for efficient detection of their post-translational modifications, with specific interests in chromatin and cancer biology.

**Nick Saccomano, PhD**
Chief Scientific Officer-Senior Vice President
Pfizer Boulder Research and Development

Nicholas A. Saccomano, PhD, currently is the Chief Scientific Officer and site head of Pfizer Boulder Research and Development. Prior to the acquisition of Array BioPharma by Pfizer in August of 2019, he served as the Chief Scientific Officer of Array Biopharma since May 2014. Prior to Array, Nick served as Chief Technology Officer at SomaLogic, Inc. and as Chief Scientific Officer at Bend Research Inc. Nick began his career at Pfizer and held positions of increasing responsibility, including Senior Vice President in the R&D organization. Also during his time at Pfizer, he led the CNS medicinal chemistry organization which brought >25 molecules to the clinic and three molecules to the market. (Chantix, Aricept and Geodon). Nick obtained his PhD in chemistry from Columbia University under the direction of Professor Gilbert Stork.

**Q&A**

**10:25 a.m.**
**CORPORATE PRESENTIONS**

**Barbara Klencke, MD**
Chief Development Officer
Sierra Oncology (SRRA)

Barbara Klencke, MD, is an accomplished oncology drug developer with a demonstrable track record of success, having made substantial contributions to the development and approval of numerous significant oncology products.

Previously, Barbara served as the Senior Vice President, Development at Onyx Pharmaceuticals, a subsidiary of Amgen Inc., from January 2011 to June 2015, and prior to that was the Group Medical Director in Product Development, Oncology at Genentech, Inc., having joined the company in July 2003. In this period, she led a variety of oncology programs including those for Kyprolis (carfilzomib), Kadcyla (ado-trastuzumab emtansine), Avastin (bevacizumab), and Tarceva (erlotinib). Prior to that, Barbara served as the Medical Director at Chiron Corporation, a biotechnology company later acquired by Novartis International AG, and as an
Mani Mohindru, PhD
Chief Executive Officer and Member, Board of Directors
CereXis

Mani Mohindru, PhD, is Chief Executive Officer of CereXis, a private biotechnology company focused on rare nervous system tumors such as Neurofibromatosis Type 2 (NF2). Previously, she served as Chief Financial and Chief Strategy Officer at Cara Therapeutics (Nasdaq: CARA) and helped raise over $200 million in secondary public offerings. Prior to that, she was Chief Strategy Officer of Curis (Nasdaq: CRIS), an oncology drug development company. Before Curis, she spent several years on Wall Street as a biotechnology equity research analyst at multiple investment banks (UBS, Credit Suisse, and ThinkEquity). Mani has also served as a healthcare management consultant to various Biotech & Pharma companies advising companies on development and commercial strategies for both development stage candidates and marketed drugs.

Mani currently serves as a Member of the Executive Advisory Board of Chemistry of Life Processes Institute at Northwestern. She earned a PhD in Neurosciences from Northwestern University and a B.Sc (Hons) in Human Biology and Masters in Biotechnology from the All India Institute of Medical Sciences, New Delhi, India.

Jonathan Zalevsky, PhD
Chief Research and Development Officer
Nektar (NKTR)

Jonathan Zalevsky, PhD, was appointed Chief Research & Development Officer in October 2019 to lead all aspects of the R&D organization within Nektar, including research, clinical development, regulatory affairs and biologics process development. Jonathan joined the Company in 2015 and has served as our Chief Scientific Officer since 2017. During his tenure at Nektar, Jonathan’s expertise in immunology, as well as his experience across biological modalities and therapeutic areas, have helped fuel the growth of the company’s immuno-oncology and immunology pipeline. Jonathan led the early development for NKTR-214 (bempegaldesleukin, a CD122 preferential IL-2 pathway agonist being developed for the treatment of multiple cancers with partner Bristol-Myers Squibb) and NKTR-358 (a T regulatory cell stimulatory agent being developed for auto-immune diseases with partner Eli Lilly & Co.).
Prior to joining Nektar, Jonathan was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and launched products. Prior to working at Takeda, Jonathan held a number of research and development positions at Xencor, where he was responsible for the discovery and development of Xencor’s first four clinical-stage assets.

Jonathan received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual bachelor degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.

Q&A

11:25 a.m.

PANEL DISCUSSION: MIDWEST BIOTECH INVESTMENT OUTLOOK

Moderator:

Jay Olson, CFA,
Research Analyst
Oppenheimer & Co.

Jay Olson, CFA, is Managing Director and Senior Analyst covering Biotechnology since 2016. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for four years after four years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development.

Jay received an MBA in Finance and an MS in Chemical Engineering, both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.

Panelists:

Vanessa Bhark
Senior Associate
Frazier Healthcare Partners

Vanessa Bhark joined Frazier Healthcare Partners as Senior Associate in 2018. She focuses on evaluating investments and creating new ventures in life sciences.

Prior to joining Frazier, Vanessa was in Corporate Development at Gilead Sciences, where she structured and led the negotiation of licenses, collaborations, and acquisitions across therapeutic areas. Previously, Vanessa was a Business Development Manager at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where she led the evaluation and recommendation of licensing and acquisition opportunities for Janssen’s $3.2B Infectious Disease Franchise. In addition, Vanessa worked for Morgan Stanley in the Equity Research Division with a focus on public biotech investments.
Vanessa holds a B.S. in Chemical Engineering from MIT and an M.B.A. from the Kellogg School of Management at Northwestern University.

**Maha Katabi, PhD, CFA**  
General Partner  
Sofinnova Investments

Maha Katabi, PhD, CFA, joined Sofinnova as a Partner in 2019. In 2020, she was promoted to General Partner. She focuses on development stage investments in therapeutics. Maha represents Sofinnova as a member of the board of directors for Northsea Therapeutics.

Prior to joining Sofinnova, Maha was a Managing Partner of Oxalis Capital. She is an experienced investor in biopharma companies, with over two decades in venture capital investing and public equities portfolio management. Prior to founding Oxalis in 2018, Maha was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Additionally, she was a Portfolio Manager for a family of funds that invested in publicly listed and private healthcare companies. Prior to Sectoral, Maha was Vice-President at Ventures West Management since 2004, a venture capital firm focusing on technology and life sciences in Canada and the United States. She started her venture capital career in 1999 at T2C2 Capital Bio, a seed fund focused on Canadian start-ups.

Maha received her PhD in Pharmacology and BSc in Biology from McGill University, and is a CFA charterholder. She is currently Chair of the board of Exactis Innovation, an oncology precision medicine network, and serves on the board of BIOQuébec, an industry association active in the healthcare sector in Canada.

**Michael Margolis, RPh**  
Managing Director  
Oppenheimer & Co.

Michael Margolis, RPh, joined Oppenheimer & Co. Inc. in 2017 where he currently serves as Co-Head of Healthcare Investment Banking. He has over two decades of Investment Banking experience in the Life Sciences sectors. Prior to joining Oppenheimer, Michael served as the Head of Healthcare Investment Banking at Roth Capital Partners, LLC, and as a Managing Director at Merriman Holdings, Inc. (also known as Merriman Curhan Ford Group Inc.). Before becoming an Investment Banker, Michael worked at Novartis Pharmaceuticals Corporation in several roles and at Ursus Capital. He began his career at Eli Lilly & Company as a Senior Pharmaceutical Representative. Michael is a registered Pharmacist and holds an MBA from New York University’s Stern School of Business and a Pharmacy Degree from Rutgers University, College of Pharmacy.
Alex Munns is an assistant portfolio manager on the US Growth Equities Team with a focus on the health care sector. His in-depth fundamental research, idea generation and buy/sell recommendations are leveraged across all four of the strategies managed by the Driehaus US Growth Equities Team. Additionally, specific to the Driehaus Life Sciences strategy, Alex acts as an assistant portfolio manager and is also responsible for security selection, portfolio construction, and risk management.

Alex has been working with or investing in health care companies since 2011. Before joining Driehaus Capital Management in 2015, Alex worked in oncology commercialization and business development with Baxalta where he performed due diligence on assets across oncology and hematology. Prior to that, he worked in business development for Terumo Cardiovascular Systems, managing contracts between the company, its suppliers, and due diligence. Alex has also taught for Teach for America in Chicago.

Alex received a B.A. from Yale University and an M.B.A. from the University of Michigan Ross School of Business.

Q&A
and Parkinson’s. Together, we accelerate the delivery of revolutionary science that improves lives and transforms human health.

clp.northwestern.edu

**Oppenheimer & Co. Inc.**

For more than 130 years, Oppenheimer & Co. Inc. has provided our clients with the financial expertise and insight to help achieve their goals. Oppenheimer’s proud tradition of providing innovative, customized solutions to our clients sets us apart from our competitors. We believe in independent thinking that leads to innovative strategies tailored to the needs of our clients. Oppenheimer is proud of its reputation as a Firm that helps individuals, families, corporate executives, foundations and endowments, charities, pension plans, businesses, and institutions.

oppenheimer.com